Searchable abstracts of presentations at key conferences in endocrinology

Endocrine Abstracts

Published by BioScientifica

Page 1 of about 3 results

ea0089b8 | Basic Science | NANETS2022

CDK4/6-MEK Targeted Therapy Causes Regression and Reduced Metastatic Colonization of Pancreatic Neuroendocrine Tumors

Kaemmer Courtney , Umesalma Shaikamjad , Maharjan Chandra , Kohlmeyer Jordan , Wilkerson Emily , Sheehy Ryan , Leidinger Mariah , Meyerholz David , Bell Sarah , Zamba Gideon , Breheny Patrick , Lattime Edmund , Chandrasekharan Chandrikha , Bellizzi Andrew , Herring Laura , Graves Lee , Darbro Benjamin , Yuan Ziqiang , Libutti Steven , Quelle Dawn

Background: New therapeutics and combinations are needed to improve the survival of patients with advanced, metastatic pancreatic NETs (pNETs). RABL6A is a novel oncogenic driver of pNET pathogenesis that acts through multiple oncogenic pathways. Kinome and phosphoproteome analyses of proliferating (RABL6A-positive) pNET cells, vs arrested (RABL6A-knockdown) controls, demonstrated that druggable cyclin-dependent kinase 4 and 6 (CDK4/6) and MEK kinases are activated in growing ...
0 shares

ea0098b15 | Basic Science | NANETS2023

Investigating serotonin metabolism in neuroendocrine cancers

Tow Dane H. , Ridder Maclain , Tran Catherine G. , Borbon Luis C. , Li Guiying , Kaemmer Courtney A. , Abusada Ellen , Harish Mahalingam Aswanth , Sadanandam Anguraj , Chandrasekharan Chandrikha , Dillon Joseph , Spitz Douglas R. , Quelle Dawn E. , H.F. Chan Carlos , Bellizzi Andrew , Howe James R. , Po Hien Ear and

Background: Small bowel neuroendocrine tumors (SBNETs) originate from enterochromaffin cells in the intestine which synthesize and secrete serotonin. Other NETs and other cancers may also produce serotonin but do not store them in vesicles. The rate limiting enzyme of serotonin biosynthesis is tryptophan hydroxylase 1 (Tph1). Patients with high serotonin level could develop carcinoid syndrome, which can be treated with somatostatin analogues and the Tph1 inhibitor telotristat ...
0 shares

ea0098b28 | Basic Science | NANETS2023

Therapies targeting CDK4/6 cause regression, immune cell activation, and sensitization to PD-L1 immunotherapy in pancreatic neuroendocrine tumors

Kaemmer Courtney , Umesalma Shaikamjad , Maharjan Chandra , Kohlmeyer Jordan , Lingo Joshua , Wilkerson Emily , Sheehy Ryan , Leidinger Mariah , Meyerholz David , Bell Sarah , Zamba Gideon , Breheny Patrick , Lattime Edmund , Chandrasekharan Chandrikha , Bellizzi Andrew , Herring Laura , Graves Lee , Darbro Benjamin , Yuan Ziqiang , Libutti Steven , Quelle Dawn

Background: New effective therapies are needed to improve the survival of patients with metastatic pancreatic NETs (pNETs). RABL6A is a novel oncogenic driver of pNET pathogenesis. Kinome and phosphoproteome analyses of proliferating (RABL6A-positive) pNET cells, vs arrested (RABL6A-knockdown) controls, demonstrated that cyclin-dependent kinase 4 and 6 (CDK4/6) and MEK kinases are actionable drug targets in growing pNET cells. In agreement, published studies of patient pNETs b...
0 shares

Published by BioScientifica

Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 | Privacy policy | Cookie settings

BiosciAbstracts

Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.

Find out more